Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2024 09:00 ET | Source: DepYmed, Inc.

DepYmed to Present at the 9th World Rett Syndrome Congress

FARMINGDALE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...
March 19, 2024 10:59 ET | Source: DepYmed, Inc.

DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome

FARMINGDALE, N.Y., March 19, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a clinical-stage pharmaceutical company focused on developing transformative medicines for many...
February 21, 2024 09:35 ET | Source: DepYmed, Inc.

DepYmed to Meet with Investors at the BIO CEO and Investor Conference

FARMINGDALE, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
February 07, 2024 09:45 ET | Source: DepYmed, Inc.

DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference

FARMINGDALE, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
October 03, 2023 09:45 ET | Source: DepYmed, Inc.

DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023

FARMINGDALE, N.Y., Oct. 03, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
September 27, 2023 09:45 ET | Source: DepYmed, Inc.

DepYmed to Meet with Investors at the BioFuture Conference in New York City October 4-6, 2023

FARMINGDALE, N.Y., Sept. 27, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
June 15, 2023 09:00 ET | Source: DepYmed, Inc.

DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting

FARMINGDALE, N.Y., June 15, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
May 31, 2023 09:30 ET | Source: DepYmed, Inc.

DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting

FARMINGDALE, New York, May 31, 2023 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for...
November 16, 2022 09:35 ET | Source: DepYmed, Inc.

DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome

FARMINGDALE, N.Y., Nov. 16, 2022 (GLOBE NEWSWIRE) -- DepYmed, Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...
May 23, 2022 09:45 ET | Source: DepYmed, Inc.

DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease

FARMINGDALE, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- DepYmed Inc. (“DepYmed” or the “Company”) is a preclinical stage pharmaceutical company focused on developing transformative treatments for rare...

Next Page keyboard_arrow_right